Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

To join this study, you need to be an adult aged 18 or older and have an advanced solid tumour (meaning cancer that forms a lump, not blood cancer) that has already been treated at least once for advanced stages, but the treatment wasn't successful. Your cancer must also have specific changes in the HER2 protein, which your doctors would have already identified.

There are also some reasons why you might not be able to join. For example, if you have a certain type of lung cancer (HER2 mutant Non-small cell lung cancer), or if you've had other cancers recently that aren't fully cured (though some very common, treatable cancers might be okay). Also, if you need to take other medicines that would interfere with the study medicine, or if you've had major surgery recently, you might not be able to participate. The study doctor will go through all these details with you.

To help the researchers, you also need to be willing to provide a small sample of your cancer tissue that was taken during a previous surgery or biopsy.

If you decide to take part, you'll be given the medicine zongertinib, usually once a day. The exact dose will depend on which group you're in. You can continue taking the medicine for as long as it seems to be helping you and you feel well enough to take it. You'll have regular visits to the study clinic.

During many of these visits, the doctors will check to see how the tumour is responding and if it has spread. At every visit, they will carefully check your overall health and ask about any new feelings or side effects you might be having. These check-ups are very important for your safety and to help the researchers understand how the medicine is working. The study team will explain how often these visits are and what they involve in detail.